Jump to content

All Activity

This stream auto-updates     

  1. Today
  2. Yesterday
  3. Funding for #IBS is 25x lower than conditions that are 30x less common. Does that make sense? That's why research in #IBS and #SIBO is so slow. But working with fewer bricks doesn't mean we stop working. Patients need new treatments. (Feed generated with FetchRSS) View the full article
  4. Vascular endothelial growth factor, endostatin levels and clinical features among patients with ulcerative colitis and irritable bowel syndrome and among healthy controls: a cross-sectional analytical study. Sao Paulo Med J. 2018 Nov-Dec;136(6):543-550 Authors: Aksoy EK, Çetinkaya H, Savaş B, Ensari A, Torgutalp M, Efe C Abstract BACKGROUND: Increased angiogenetic activity in inflammatory bowel disease (IBD) has been shown in previous studies. The aim of this study was to evaluate the relationship of serum vascular endothelial growth factor (VEGF) and endostatin levels with clinical features and mucosal expression in patients with ulcerative colitis (UC). DESIGN AND SETTING: Cross-sectional analytical study conducted in a tertiary-level public hospital. METHODS: Serum VEGF and endostatin levels were determined in 82 individuals: 39 with UC, 28 with irritable bowel syndrome (IBS) and 15 healthy controls (HCs), using enzyme-linked immunosorbent assays (ELISA). VEGF and endostatin expressions were studied using immunohistochemistry (IHC). RESULTS: Mean serum VEGF and endostatin levels were significantly higher in patients with UC than in patients with IBS and in HCs (511.9 ± 377.5 pg/ml, 305.0 ± 121.42 pg/ml and 36.1 ± 40.6 pg/ml; P = 0.001 for VEGF; and 155.50 ± 59.8 ng/ml, 116.9 ± 23.8 ng/ml and 102.2 ± 22.4 ng/ml; P < 0.001 for endostatin, respectively). There was a positive correlation between serum VEGF and endostatin levels (r = 0.422; P < 0.01). Mean H-scores for VEGF expression were higher in the active UC group than in the inactive UC and IBS groups, in the stroma, endothelium and epithelium. Mean H-scores for endostatin expression were higher in the active UC group than in the inactive UC and IBS groups, in the stroma and endothelium. There was no endostatin expression in the epithelium. CONCLUSION: Increased endostatin appears to be a defensive reaction to increased VEGF in patients with UC. PMID: 30892485 [PubMed - in process] View the full article
  5. Related Articles Electroacupuncture is Not Effective For Comorbid Generalized Anxiety Disorder & Irritable Bowel Syndrome. J Gastroenterol Hepatol. 2019 Mar 19;: Authors: Mak DPA, Chung CHV, Suet Ying Y, Tse YK, Wong YSS, Ju Y, Hung SS, Leung KC, You HSJ, Lui R, Wong SH, Leung NWO, Lam CWL, Lee S, Wu CJ Abstract BACKGROUND AND AIM: Comorbid generalized anxiety disorder and irritable bowel syndrome are common and therapeutically challenging. We aimed to assess the effectiveness of electroacupuncture in relieving anxiety and bowel symptoms in Chinese adults with this form of comorbidity. METHODS: In a single-blind randomized sham-controlled trial, subjects with comorbid generalized anxiety disorder and irritable bowel syndrome were randomly assigned to receive 10 weekly sessions of electroacupuncture or sham electroacupuncture. Patients were assessed at baseline, immediately after intervention and at 6-week follow-up. Primary outcome was anxiety (7-item Patient Health Questionnaire section for anxiety) . Secondary outcomes included bowel symptoms (bowel symptoms questionnaire), depressive symptoms (9-item Patient Health Questionnaire), somatic symptoms (15-item Patient Health Questionnaire) and health-related quality of life (Euroqol-5 dimensions). RESULTS: 80 subjects, 40 in each arm, were randomized. All but 2 in the sham group completed 10 weekly sessions. There was no significant difference in the proportion of patients experiencing significant (>/= 50%) reduction of anxiety symptoms between the two groups immediately after intervention (32.4% vs 21.6%, p=0.06) and at 6-week follow-up (25.7% in electroacupuncture vs 27% in sham, p=0.65). Anxiety, depressive, bowel symptom severity did not differ significantly between electroacupuncture and sham groups. CONCLUSIONS: Findings failed to support the effectiveness of electroacupuncture for comorbid generalized anxiety disorder and irritable bowel syndrome. Further studies are needed to identify effective acupuncture treatment protocols for such comorbidity. PMID: 30891824 [PubMed - as supplied by publisher] View the full article
  6. An update of the scientific evidence behind the microbiota-specific effects of common dietary patterns Gut Microbiota for HealthDiet is the most widely studied modifiable factor for shaping gut microbiota composition and function and we are beginning to understand how isolated ... View the full article
  7. Last week
  8. I Suffered from Severe IBS for 18 Years till One Treatment Changed Everything Reader's DigestNearly 16 million Americans suffer from IBS-D, or irritable bowel syndrome with diarrhea. Dawn Cobb suffered for almost two decades and thought surgery was ... View the full article
  9. RT @ANMSociety: This is a great resource for providers and patients. Having a dietitian as part of your plan of care is important. https://… (Feed generated with FetchRSS) View the full article
  10. Calling all DIETITIANS & HCPs! Our online course ' The low FODMAP diet for IBS' has been updated with more up to date info, more pt education material and end of module fact sheets. Click here to read more AND preview the course: https://bit.ly/2TfQico (Feed generated with FetchRSS) View the full article
  11. Related Articles Irritable bowel syndrome in Egyptian patients: plausible risk factors and association with intestinal protozoa. Trop Doct. 2019 Mar 18;:49475519837112 Authors: Salem AI, El-Taweel HA, Madkour MA, Abd El-Latif NF, Abd-Elrazeq ES Abstract The pathogenesis of irritable bowel syndrome (IBS) is not yet clear. Our study suggested parasitic infection and other plausible risk factors among Egyptian IBS patients. We studied 40 IBS patients diagnosed according to Rome III criteria (Group I), 40 with other gastrointestinal symptoms (Group II) and 40 healthy controls (Group III). Stool samples were examined using direct wet smear, sedimentation technique, trichrome stain and immune-chromatographic tests for Cryptosporidium parvum. IBS patients displayed a significantly greater percentage of Blastocystis hominis infection (45%) than non-IBS patients (20%) and healthy controls (10%). Dientamoeba fragilis was identified in two IBS patients. Detection of B. hominis was independent of demographic characters, IBS subtype, Helicobacter pylori infection or medications, but with a positive association with a history of antibiotic intake with IBS. PMID: 30885054 [PubMed - as supplied by publisher] View the full article
  12. Related Articles Personalized medicine in functional gastrointestinal disorders: Understanding pathogenesis to increase diagnostic and treatment efficacy. World J Gastroenterol. 2019 Mar 14;25(10):1185-1196 Authors: Wang XJ, Camilleri M Abstract There is overwhelming evidence that functional gastrointestinal disorders (FGIDs) are associated with specific mechanisms that constitute important targets for personalized treatment. There are specific mechanisms in patients presenting with functional upper gastrointestinal symptoms (UGI Sx). Among patients with UGI Sx, approximately equal proportions (25%) of patients have delayed gastric emptying (GE), reduced gastric accommodation (GA), both impaired GE and GA, or neither, presumably due to increased gastric or duodenal sensitivity. Treatments targeted to the underlying pathophysiology utilize prokinetics, gastric relaxants, or central neuromodulators. Similarly, specific mechanisms in patients presenting with functional lower gastrointestinal symptoms, especially with diarrhea or constipation, are recognized, including at least 30% of patients with functional constipation pelvic floor dyssynergia and 5% has colonic inertia (with neural or interstitial cells of Cajal loss in myenteric plexus); 25% of patients with diarrhea-predominant irritable bowel syndrome (IBSD) has evidence of bile acid diarrhea; and, depending on ethnicity, a varying proportion of patients has disaccharidase deficiency, and less often sucrose-isomaltase deficiency. Among patients with predominant pain or bloating, the role of fermentable oligosaccharides, disaccharides, monosaccharides and polyols should be considered. Personalization is applied through pharmacogenomics related to drug pharmacokinetics, specifically the role of CYP2D6, 2C19 and 3A4 in the use of drugs for treatment of patients with FGIDs. Single mutations or multiple genetic variants are relatively rare, with limited impact to date on the understanding or treatment of FGIDs. The role of mucosal gene expression in FGIDs, particularly in IBS-D, is the subject of ongoing research. In summary, the time for personalization of FGIDs, based on deep phenotyping, is here; pharmacogenomics is relevant in the use of central neuromodulators. There is still unclear impact of the role of genetics in the management of FGIDs. PMID: 30886502 [PubMed - in process] View the full article
  13. The juvenile fibromyalgia syndrome (JFMS): a poorly defined disorder. Acta Biomed. 2019 Jan 23;90(1):134-148 Authors: De Sanctis V, Abbasciano V, Soliman AT, Soliman N, Di Maio S, Fiscina B, Kattamis C Abstract Juvenile fibromyalgia syndrome (JFMS) is a chronic condition characterized by symptoms of chronic diffuse musculoskeletal pain and multiple painful tender points on palpation. It is often accompanied by fatigue, disorders of sleep, chronic headaches, irritable bowel syndrome, and subjective soft tissue swelling. The complexity of the presenting clinical picture in JPFS has not been sufficiently defined in the literature. Similarities to adult fibromyalgia syndrome in JFMS are often difficult to compare, because many of the symptoms are "medically unexplained" and often overlap frequently with other medical conditions. However, a valid diagnosis of JFMS often decreases parents' anxiety, reduces unnecessary further investigations, and provides a rational framework for a management plan. The diagnostic criteria proposed by Yunus and Masi in 1985 to define JFMS were never validated or critically analyzed. In most cases, the clinical diagnosis is based on the history, the physical examination that demonstrates general tenderness (muscle, joints, tendons), the absence of other pathological conditions that could explain pain and fatigue, and the normal basic laboratory tests. Research and clinical observations defined that JFMS may have a chronic course that impacts the functional status and the psychosocial development of children and adolescents. This paper briefly reviews the existing knowledge on JFMS focusing on the diagnosis, clinical and the epidemiological characteristics in children and adolescents for better understanding of this disorder. PMID: 30889168 [PubMed - in process] View the full article
  14. Stomach bloating: Are your IBS symptoms, pain and cramps actually coeliac disease? ExpressSTOMACH bloating, pain and cramps are often associated with irritable bowel syndrome, but symptoms of IBS could actually be a sign of coeliac disease, a UK ... View the full article
  15. Should You Take Probiotics Whilst Travelling? News-Medical.netTraveling to a new destination can be an exhilarating experience; however, traveling also means different food, different water, different time-zones and ... View the full article
  16. ibsc guy

    So tired of this.

    hi becky have u tried enemas yet?
  17. ibsc guy

    Bloating and hard lower abdomen

    hi country girl , i know what u going thru i have had ibs c s for over 22 years
  18. ibsc guy

    SoCal Support Group

    hi shanti,im in anaheim ,id be glad to pick you up if need be to get to the meetings,i have IBS- C
  19. ibsc guy

    SoCal Support Group

    im in anaheim dede
  20. What our bowel movements say about our health according to 5 experts Body and SoulThe experts weigh in on the dos and don'ts of number twos. View the full article
  21. ibsc guy

    SoCal Support Group

    Hi dede im also in so calif ,id like to join too
  22. RT @JohannahRuddy: Did you hear the news? The @RomeFoundation has its own app! It’s available now on the Apple Store and also available for… (Feed generated with FetchRSS) View the full article
  23. Glutamin verbessert Symptome des Reizdarmsyndroms, das nach enteraler Infektion auftritt. Praxis (Bern 1994). 2018 Nov;107(23):1289-1290 Authors: Steurer J PMID: 30424686 [PubMed - indexed for MEDLINE] View the full article
  24. Cannabis use disorders may protect against certain disorders of the digestive organs in people with schizophrenia but not in healthy controls. Psychol Med. 2019 Mar 18;:1-8 Authors: Olesen JA, Posselt CM, Poulsen CH, Nordentoft M, Hjorthøj C Abstract BACKGROUND: Previous studies have shown a potential for cannabis in disorders of the digestive organs. We aimed to investigate whether cannabis use disorders (CUD) would decrease the risk of incident disorders of the digestive organs, in people with schizophrenia and population controls. METHODS: We combined nationwide Danish registers to identify 21 066 cases with schizophrenia and 176 935 sex-and-age-matched controls. Two models were analyzed for the associations between CUD and digestive disorders in time-varying Cox regressions: one adjusted for sex, year of birth, and calendar year; and one further adjusted for alcohol and other substance use disorders and parental education. RESULTS: CUD was associated with a decreased risk of developing disorders of gut-brain interaction (e.g. irritable bowel syndrome, dyspepsia, etc.) among cases with schizophrenia (HR = 0.84, 95% CI 0.74-0.94, p = 0.003). CUD was associated with decreased risk of inflammatory bowel disease (HR = 0.70, 95% CI 0.49-0.99, p = 0.045) in the basically adjusted model, dropping just below statistical significance in the fully adjusted model (HR = 0.71, 95% CI 0.48-1.03, p = 0.07). CUD displayed a tendency toward a decreased risk of serious disorders of the digestive organs among cases with schizophrenia (HR = 0.89, 95% CI 0.77-1.02, p = 0.09) in the fully adjusted model. No associations were observed among controls. CONCLUSIONS: In people with schizophrenia, but not in controls, CUD is associated with decreased risk of disorders of gut-brain interaction and inflammatory bowel disease, and possibly other serious disorders of the digestive organs. Our findings could lead to new targets for treatment and prevention of disorders of the digestive organs. PMID: 30880659 [PubMed - as supplied by publisher] View the full article
  25. Characteristic dysbiosis of gut microbiota of chinese patients with diarrhea-predominant irritable bowel syndrome by an insight into the pan-microbiome. Chin Med J (Engl). 2019 Mar 04;: Authors: Wang Z, Xu CM, Liu YX, Wang XQ, Zhang L, Li M, Zhu SW, Xie ZJ, Wang PH, Duan LP, Zhu HQ Abstract BACKGROUND: Irritable bowel syndrome (IBS) is reported associated with the alteration of gut microbial composition termed as dysbiosis. However, the pathogenic mechanism of IBS remains unclear, while the studies of Chinese individuals are scarce. This study aimed to understand the concept of dysbiosis among Chinese diarrhea-predominant IBS (IBS-D) patients, as a degree of variance between the gut microbiomes of IBS-D population and that of healthy population. METHODS: The IBS-D patients were recruited (assessed according to the Rome III criteria, by IBS symptom severity score) from the Outpatient Department of Gastroenterology of Peking University Third Hospital, and volunteers as healthy controls (HC) were enrolled, during 2013. The 16S rRNA sequences were extracted from fecal samples. RDP resources, BLAST and SparCC software were used to obtain the phylotype composition of samples and the internal interactions of the microbial community. Herein, the nonparametric test, Wilcoxon rank-sum test was carried out to find the statistical significance between HC and IBS-D groups. All the P values were adjusted to q values to decrease the error rate. RESULTS: The study characterized the gut microbiomes of Chinese IBS-D patients, and demonstrated that the dysbiosis could be characterized as directed alteration of the microbiome composition leading to greater disparity between relative abundance of two phyla, Bacteroidetes (Z = 4.77, q = 1.59 × 10) and Firmicutes (Z = -3.87, q = 5.83 × 10). Moreover it indicated that the IBS symptom features were associated with the dysbiosis of whole gut microbiome, instead of one or several certain genera even they were dominating. Two genera, Bacteroides and Lachnospiracea incertae sedis, were identified as the core genera, meanwhile the non-core genera contribute to a larger pan-microbiome of the gut microbiome. Furthermore the dysbiosis in IBS-D patients was associated with a reduction of network complexity of the interacted microbial community (HC vs. IBS-D: 639 vs. 154). The disordered metabolic functions of IBS-D patients were identified as the potential influence of gut microbiome on the host (significant difference with q < 0.01 between HC and IBS-D). CONCLUSIONS: This study supported the view of the potential influence of gut microbiome on the symptom of Chinese IBS-D patients, and further characterized dysbiosis in Chinese IBS-D patients, thus provided more pathological evidences for IBS-D with the further understanding of dysbiosis.This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0. PMID: 30882461 [PubMed - as supplied by publisher] View the full article
  26. Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of Clostridium difficile by Fecal Microbiota Transplantation (FMT). J Clin Gastroenterol. 2019 Mar 13;: Authors: Allegretti JR, Kassam Z, Fischer M, Kelly C, Chan WW Abstract BACKGROUND: Fecal microbiota transplantation (FMT) is a promising therapy for recurrent Clostridioides difficile infection (CDI). Many patients report altered bowel habits including constipation, bloating, gas and loose stool post-FMT despite resolution of CDI, and the etiology remains unclear. METHODS: This was a prospective cohort study of adult patients with recurrent CDI who underwent FMT (1) via colonoscopy with patient-selected donor stool, (2) via colonoscopy from a universal stool bank donor, or (3) via capsules from a universal stool bank. Reassessment occurred 8 weeks post-FMT. Those cured were assessed for gastrointestinal symptoms (bloating, loose stools, constipation). Multivariate logistic regression was performed to assess predictors of post-FMT gastrointestinal symptoms. RESULTS: A total of 150 subjects underwent FMT for recurrent CDI, of which 68.7% (103) were female, mean age was 61.5 years±18.1 and 31 patients (20.7%) had preexisting irritable bowel syndrome. Thirty-six had FMT via colonoscopy with a patient-selected donor, 67 via colonoscopy with stool bank donors, and 47 via FMT capsules from stool bank donors. Among those cured, 41 (31.2%) had gastrointestinal symptoms post-FMT. The factors associated with symptoms included younger age (57.2 vs. 64.1 y, P=0.03), a baseline history of irritable bowel syndrome (36.6% vs. 13.3%, P=0.002) and preexisting inflammatory bowel disease (31.7% vs. 10%, P=0.002). Small bowel exposure to donor stool was not related to symptoms (63.4% vs. 62.2%, P=0.89). CONCLUSIONS: Altered bowel habits are a consequence of CDI and are common after FMT. This study suggests that donor type and FMT delivery modality are not related to the presence of irregular gastrointestinal symptoms after FMT. PMID: 30882536 [PubMed - as supplied by publisher] View the full article
  27. shantichakra

    SoCal Support Group

    Thank you, Dede and all, I am in Woodland Hills so Irvine is a hike for me but pls let me know once you have it. It would be great to meet up with people to support each other. Do you know anyone in LA area? I am having hard time finding IBS support group around here for some time. How are you feeling you all? How are your tummies behaving today? Anyone with SIBO or candida? Be well, Shanti.
  1. Load more activity

Clinical Advertisement

  • Create New...